IFF to Sell Food Ingredients Unit in $4.3 Billion Asset Deal
The divestiture sharpens the company’s focus on higher-margin segments and strengthens its balance sheet.
**International Flavors & Fragrances (IFF) agreed to sell its Food Ingredients business in a $4.3 billion asset-purchase transaction**, advancing a portfolio transformation aimed at concentrating resources on higher-growth, higher-margin segments.
The deal, structured as an asset sale, does not include a disclosed exchange ratio or premium, as the business is not publicly traded. IFF expects the transaction to close in the second half of 2026, subject to customary regulatory and closing conditions.
IFF framed the divestiture as a strategic milestone in its portfolio optimization initiative. "This transaction represents an important strategic milestone in our ongoing portfolio optimization initiative, allowing us to further concentrate resources on our higher-growth, higher-margin segments," said Erik Fyrwald, CEO of IFF. "By simplifying our portfolio to where we can create the greatest value, IFF will accelerate innovation, drive investment in R&D, and further integrate our biotechnology and naturals capabilities more effectively across our global platform". The company said the move would strengthen its balance sheet and enhance value creation for shareholders.
The Food Ingredients business, while not detailed in the release, has been part of IFF’s broader portfolio of taste, scent, and nutrition solutions. The divestiture aligns with a broader industry trend of conglomerates streamlining operations to focus on core, high-margin segments, particularly in specialty chemicals and ingredients.
Recent precedent deals in the sector underscore the cycle of portfolio refinement. In January 2026, B&G Foods acquired the College Inn and Kitchen Basics brands from bankrupt Del Monte Foods for $110 million, a transaction that was immediately accretive to earnings and free cash flow. Similarly, in April 2025, Amcor completed the sale of its Specialty Tapes business for $443 million, recognizing a $175 million pre-tax gain as part of a broader restructuring effort.
The IFF transaction is expected to generate proceeds that will be used to reduce debt and fund growth initiatives in its remaining businesses. The company has not disclosed specific accretion or synergy targets but indicated that the divestiture would support increased investment in R&D and biotechnology integration. Regulatory approvals and customary closing conditions remain the key hurdles before the deal is finalized.